HAYWARD, Calif. - Benitec Biopharma Inc. (NASDAQ:BNTC) announced Tuesday that interim clinical results from its BB-301 Phase 1b/2a study for Oculopharyngeal Muscular Dystrophy will be presented at the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results